Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 311 across all filing types
Latest filing 2022-02-22 Earnings Release
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a significant change (30% or more) in revenue or profit structure. It provides a summary of financial performance (revenue, operating profit, net income) comparing the current fiscal year to the previous one. While it contains financial data, it is a preliminary announcement of financial results rather than a full Annual Report (10-K) or a comprehensive Interim Report (IR). In the context of Korean regulatory filings (DART), this is a standard 'Earnings Release' or 'Preliminary Financial Results' announcement. FY 2021
2022-02-22 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' (투자판단 관련 주요경영사항) disclosure. It details the results of a Phase 3 clinical trial for a new drug (DWP16001). Since this is a specific regulatory disclosure regarding business operations and clinical trial outcomes rather than a general report, it falls under the 'Regulatory Filings' category.
2022-02-17 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경(자회사의 주요경영사항)
Earnings Release Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a significant change in financial structure (revenue/profit change of 30% or more). It provides preliminary financial data and explicitly states that these figures are subject to change following an external audit, advising readers to check the final audit report later. This is a standard regulatory disclosure of financial results (Earnings Release) rather than the final audited Annual Report or a mere announcement of a report's publication. FY 2021
2022-02-15 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from Daewoong regarding the results of a Phase 3 clinical trial for a new drug (DWP16001). It follows the standard format for 'Major Management Matters' (주요경영사항) filings in the Korean market, which are used to disclose material events such as clinical trial outcomes. Since it does not fit into specific categories like financial reports, dividends, or governance, and is a mandatory regulatory disclosure of a material event, it is classified as a Regulatory Filing (RNS).
2022-01-14 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding the results of a Phase 3 clinical trial for a diabetes drug. It details the clinical trial methodology, results, and future regulatory plans. Since it is a specific announcement of a material corporate event (clinical trial results) filed with a regulatory body, it falls under the 'Regulatory Filings' category as it does not fit into more specific categories like financial reports or shareholder meeting materials.
2022-01-14 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of a product approval application for 'Nabota' to the Chinese National Medical Products Administration (NMPA). As this is a specific regulatory announcement regarding a business development/product filing that does not fit into financial reporting, dividend, or governance categories, it is classified as a general regulatory filing.
2021-12-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.